BioCentury | Mar 23, 2020
Product Development

March 23 Quick Takes: Venclexta combo hits in AML; plus Jardiance rebuffed, Zolgensma approved in Japan and Zealand-Boehringer

Venclexta combo shows survival benefit in AML Partners Roche (SIX:ROG; OTCQX:RHHBY) and AbbVie Inc. (NYSE:ABBV) said Venclexta venetoclax plus azacitidine significantly improved overall survival and composite complete remission rate among acute myelogenous leukemia (AML) patients...
BioCentury | Oct 23, 2019
Company News

Oct. 22 Company Quick Takes: Zealand acquires Encycle; plus Novartis, Vitalis, Roche-Spark

Zealand expands peptide platform with Encycle acquisition Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) said it will expand its peptide therapeutics platform through the acquisition of Encycle Therapeutics Inc. In return for all its outstanding shares, access...
BioCentury | Oct 17, 2019
Company News

Deal streak continues for Alexion as Achillion’s story hits $930M high note

Alexion’s proposed takeout of Achillion would complete a 21-year journey that saw the latter evolve from an antiviral play into a complement pathway company. For Alexion, it represents the next step in its quest to...
BioCentury | Oct 11, 2019
Company News

Alexion deal lends late-stage support to Stealth

Alexion continued its run of deals by obtaining an option to a Phase III candidate from Stealth, which would get a boost in building its commercial infrastructure ahead of a regulatory submission next year and...
BioCentury | Sep 6, 2019
Company News

Management tracks: Prometheus, Step, Spero, NorthSea, Aristea, MODAG and more

Salix’s Mark McKenna will become CEO of gastroenterology and autoimmune disease company Prometheus Biosciences Inc. (San Diego, Calif.), formerly known as Precision IBD Inc. McKenna was president at Salix Pharmaceuticals Ltd., a subsidiary of Bausch...
BioCentury | Sep 5, 2019
Financial News

Sept. 5 Financial Quick Takes: Zealand raises cash as it readies NDA; plus Bellus, Aerie, LNC, Veralox and Sigrid

Ahead of NDA submission, Zealand raising cash Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) is raising DKK559.6 million ($82.4 million) via a private placement and directed share issue to existing investor Van Herk Investments. Zealand will sell...
BioCentury | Aug 29, 2019
Company News

Management tracks: Reata, Scholar Rock, Vaccitech, Amunix, Azitra, Ortho Clinical

Chronic and genetic diseases company Reata Pharmaceuticals Inc. (NASDAQ:RETA) hired Manmeet Soni as CFO and EVP, succeeding Jason Wilson, who will become EVP of operations. Soni was CFO of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY). Scholar Rock...
BioCentury | Jul 29, 2019
Company News

July 29 Management tracks: Verastem names CEO; plus Zealand, Turning Point, Arvinas and more

Verastem Inc. (NASDAQ:VSTM) named board member Brian Stuglik as CEO. In June, Robert Forrester stepped down as the cancer company's president and CEO; COO Dan Paterson succeeded Forrester as president and led the executive team...
BioCentury | May 14, 2019
Clinical News

May 14 Clinical Quick Takes: Myovant, Solid, Minerva, Modus, Zealand

Myovant tumbles after Phase III uterine fibroid data Myovant Sciences Ltd. (NYSE:MYOV) lost $4.39 (25%) to $12.83 Tuesday despite reporting that relugolix (TAK-385) met the primary endpoint of a better response rate than placebo in...
BioCentury | Apr 6, 2019

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
Items per page:
1 - 10 of 296